CENTER FOR RECOMBINANT GAMETE CONTRACEPTIVE VACCINOGENS

重组配子避孕中心的使命 疫苗是研制和试验一种安全、有效、可逆 避孕疫苗。 重点放在女性疫苗上， 由一种或多种重组配子相关免疫原组成 引发免疫反应， 受精 该中心协调研究和开发 产品开发计划的八个阶段 1)配子特异性分子的基础发现和评价 [疫苗原]及其来源于精子的抗原决定簇， 卵子、卵子投资或辅助生殖器官; 2）工程 将编码特定疫苗原的基因转化为适当的表达 合成肽的系统或制造; 3）生产和 在良好实验室条件下纯化重组疫苗原 实践[GLP]; 4）疫苗剂量的配制; 5）小动物和 免疫原性疫苗制剂的灵长类动物试验，安全性 6）疫苗作用机制的评价; 7）人 8）发展监测不孕症的诊断方法 有效疫苗接种者的状况。 资助NIH赠款 HD00654、HD29099、HD35523和RR00166。

The mission of the Center for Recombinant Gamete Contraceptive Vaccine is to develop and test a safe, effective, reversible contraceptive vaccine. Emphasis is placed upon a vaccine for females, consisting of one or more recombinant gamete-associated immunogens that elicit immunological responses that function to prevent fertilization. The Center coordinates research and development activities encompassing eight stages of a product development program 1) Fundamental discovery and evaluation of gamete-specific molecules [vaccinogens] and their antigenic determinants derived from the sperm, egg, egg investments, or accessory reproductive organs; 2) Engineering of genes encoding specific vaccinogens into appropriate expression systems or manufacture of synthetic peptides; 3) Production and purification of recombinant vaccinogens under good laboratory practices [GLP]; 4) Formulation of vaccine doses; 5) Small animal and primate testing of vaccine formulations for immunog eni city, safety and efficacy; 6) Evaluation of mechanisms of vaccine action; 7) Human trials; and 8) Development of diagnostics to monitor infertility status in recipients of effective vaccines. FUNDING NIH grants HD00654, HD29099, HD35523, and RR00166.